
Pivotal starts enrolment in a phase II clinical trial for patients with von Hippel-Lindau (VHL) disease developing renal cell cancer
Pivotal starts enrolment in a phase II clinical trial for patients with von Hippel-Lindau (VHL) disease developing renal cell cancer
- New collaboration aims to further accelerate the delivery of novel treatments for difficult-to-treat cancers
- Collaboration will enable patients in Europe to access novel investigational cancer therapies
The study will include up to 60 patients from US and European sites and will assess, as primary objective, the clinical benefit in terms of overall response rate in renal tumours and, as secondary objectives, duration of response, time to response, progression free survival, time to surgery, pharmacokinetics, safety and tolerability. Additionally, the trial will assess the efficacy in other disease-associated tumours. Promising results were achieved in a phase I study with this drug, showing preliminary clinical efficacy and a very good safety profile.
About Pivotal
Pivotal was founded in 2001 by Dr. Ibrahim Farr on the principle that strategic medical advice and support should be the backbone of all clinical trials. After working for over two decades in the pharmaceutical industry, Dr. Farr recognized the need for a medium-sized CRO with a solid internal medical franchise that could act not only as the "doers" but also as the “co-thinkers” for their clients, through its strategic scientific advice. To date, we are the trusted advisor and counselor for many companies to deliver maximum value in their drug development programmes. We are a leading privately-held European CRO and, since inception, we have experienced a fast and steady organic growth in Europe.
Pivotal clients’ portfolio spans major pharmaceutical, biotechnological, medical device and nutrition companies, and we have long-standing relations with over 188 clients. Pivotal has extensive experience across major therapeutic areas and phases I to IV. Our highly customized teams bring to each client a combination of broad industry knowledge and operational excellence, to offer our clients fresh perspectives and breakthrough business insights. Additionally, we have built a strong oncology, innovative therapies, rare diseases and early phases hub that enables us to tackle our customers' most difficult challenges, turning recommendations into concrete actions. By remaining true to our core principles and values, our vision is to become our client’s preferred outsourcing solution partner.
For more information, please visit www.pivotal.es
MEDIA CONTACT
Ms. Natalia Farr
M.: +34 679 488 022
natalia.farr@pivotal.es

Editor Details
-
Company:
- Pivotal
-
Name:
- Jamie Kightley
- Email:
- Website: